ABA-201

ABA-201 is an autologous regulatory T cell (Treg) therapy in development by Abata Therapeutics for the treatment of type 1 diabetes. The therapy is designed for patients who retain some beta cell function and possess a specific HLA genetic haplotype. ABA-201 is created by minimally engineering a patient’s own Tregs to express a T cell receptor (TCR) that specifically recognizes immunogenic protein fragments in the pancreas and draining lymph nodes. This targeted approach aims to limit ongoing beta-cell destruction, preserve residual beta-cell mass, promote tissue repair, and establish long-lived tissue residency. In vitro studies have shown that ABA-201 demonstrates antigen-specific, dose-dependent Treg functionality, anti-inflammatory cytokine production, and suppression of inflammatory factors produced by T cells. The goal is to provide a highly localized anti-inflammatory effect at the site of disease with a strong safety profile[1][2][4][5].